Insights from the ISABELA Trials and the Path Toward Risk Stratification & Prognostic Biomarkers in IPF
- Reviewing analyses from the ISABELA Phase 3 trials demonstrating how circulating biomarkers such as MMP-7 and CCL18 are associated with disease progression and mortality in IPF
- Understanding how large clinical datasets enable validation of prognostic biomarkers and support the development of composite risk models to stratify patients by disease trajectory
- Discussing how these insights may support patient enrichment strategies and more efficient trial design as the IPF therapeutic pipeline expands